Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

prnewswire.com - 2026-07-03 12:15:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026.

businesswire.com - 2026-06-23 07:00:00

Amylyx Pharmaceuticals NASDAQ: AMLX Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference.

marketbeat.com - 2026-06-10 18:13:38

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-10 13:52:16

[url="]Amylyx Pharmaceuticals, Inc.[/url] (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced two poster presentations at the upcoming Endocrine

gurufocus.com - 2026-06-08 10:00:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026.

businesswire.com - 2026-06-08 09:00:00

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of publicly traded securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX): SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION To: All those who purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (“Amylyx”) securities between November 11, 2022, and November 8, 2023, inclusive (the “Class Period”), and who were allegedly damaged thereby (the “Settlement Class”). YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Massachusetts, that Plaintiff Oliver Shih, on behalf of himself and all members of the proposed Settlement Class, and Amylyx, Joshua B.

globenewswire.com - 2026-06-08 08:00:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol, in adults living with Wolfram syndrome have been published in The Journal of Clinical Investigation, a peer-reviewed medical journal. The publication reports Week 24 and Week 48 results from the Phase 2 ope.

businesswire.com - 2026-05-15 12:11:00

Amylyx Pharmaceuticals NASDAQ: AMLX is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the third quarter, Co-Chief Executive Officer Joshua Cohen said at the BofA Annual Healthcare Conference.

marketbeat.com - 2026-05-14 01:06:33

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-13 20:20:47

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-07 17:01:47

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results.

businesswire.com - 2026-05-07 07:00:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the launch of a U.S. Expanded Access Program (EAP) for up to 250 adults with post-bariatric hypoglycemia (PBH) to provide treatment access to avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. The EAP allows U.S. physicians to request avexitide for adults with PBH following Roux-en-Y gastric bypass (RYGB) surgery who have a se.

businesswire.com - 2026-05-05 07:00:00

Amylyx Pharmaceuticals (NASDAQ: AMLX) is entering what it described as a pivotal year for its lead program, avexitide, with Phase 3 data expected in the third quarter and preparations underway for a potential commercial launch in 2027, Chief Financial Officer Jim Frates said during a Needham investor session hosted by biotech analyst Ami Fadia. Frates said

defenseworld.net - 2026-04-17 03:31:05